Feb 14 (Reuters) - SPK Acquisition Corp SPK.O :
* VARIAN BIOPHARMACEUTICALS, INC., A PRECISION ONCOLOGY COMPANY, TO BECOME PUBLICLY TRADED THROUGH A MERGER WITH SPK ACQUISITION CORP.
* SPK ACQUISITION CORP - COMBINED COMPANY EXPECTED TO HAVE A POST-TRANSACTION PRO FORMA EQUITY VALUE OF APPROXIMATELY $116 MILLION
* SPK ACQUISITION CORP - MERGER EXPECTED TO CLOSE IN Q2 2022, AND COMBINED COMPANY WILL BE LISTED ON NASDAQ UNDER PROPOSED TICKER SYMBOL "VBIO"
* SPK ACQUISITION CORP - CASH PROCEEDS FROM TRANSACTIONS ARE EXPECTED TO FUND MANUFACTURING, PRE-CLINICAL AND IND-ENABLING TOXICOLOGY STUDIES
* SPK ACQUISITION CORP - COMPANY WILL BE LED BY EXISTING MANAGEMENT FROM VARIAN BIO, INCLUDING CEO JEFFREY B. DAVIS AND CMO DR. JONATHAN LEWIS
Source text for Eikon: ID:nGNX1KpM4Y Further company coverage: SPK.O